Open AccessEvaluation of prescribing pattern of phosphodiesterase-5 inhibitors and assessing effectiveness of sildenafil and tadalafil in patients with erectile dysfunction
Author(s) -
Yatish Byndoor,
Tamilisetti Vidya Sagar,
Sanjay Kumar
Publication year - 2022
Publication title -
indian journal of pharmacy and pharmacology
Language(s) - English
Resource type - Journals
eISSN - 2393-9087
pISSN - 2393-9079
DOI - 10.18231/j.ijpp.2021.050
Subject(s) - tadalafil , erectile dysfunction , sildenafil , medicine , cgmp specific phosphodiesterase type 5 , vardenafil , observational study , physical therapy , urology
Several factors may affect identification and treatment of erectile dysfunction by health care providers, this study evaluates prescribing pattern of PDE-5 inhibitors and assess effectiveness of Sildenafil and Tadalafil in patients with erectile dysfunction. This is a descriptive and observational study, observed participants without providing any interventions, after fulfilling inclusion and exclusion criteria, patients were enrolled into study and informed written consent was obtained from all patients, data was obtained from medical records, analysed descriptively. International Index of Erectile Function (IIEF) Questionnaire is used in assessment of erectile dysfunction and treatment outcomes. In our study, 80% of patients were prescribed with phosphodiesterase inhibitors and 20% received nutritional supplements. 80 percent of drugs were prescribed under generic name, subjects treated with Sildenafil/Tadalafil were found to be associated with higher mean scores for questions of International Index of Erectile Function (IIEF). Tadalafil scored high in terms of sexual desire domain. PDE5 inhibitors represent major first-line oral therapy option for men with erectile dysfunction, shift of market from brand to generic products allows more freedom of choice, although multiple reports suggest general equivalency of four major PDE5 inhibitors, tadalafil suggested to be preferable.